Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.

Exploring the Interdependency between Public and Charitable Medical Research
1 April 2011
Continuing concern about the fiscal deficit makes it likely that government funding of health and medical research will remain under scrutiny. This OHE Consulting study, commissioned…

Incentives for R&D for New Antimicrobial Drugs
1 April 2011
Antimicrobial resistance (AMR) is becoming a major global public health threat and has begun to command attention from European and US policy makers. An initial focus…

Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
1 February 2011
This paper examines the potentially positive impact of differential pricing in Europe and the overall negative effects of international reference pricing (IRP) measures. The authors point…

Priority Review Vouchers to Encourage Innovation for Neglected Diseases
1 January 2011
Priority Review Vouchers (PRVs) are awarded in the US to companies that gain approval there for a new drug for one of sixteen tropical diseases, under…

Seminar Briefing on Science Policy
23 December 2010
At a recent OHE seminar, Prof Ben Martin (Science and Technology Policy Studies at SPRU, University of Sussex) presented the results of his extensive literature review…

Report on Orphan Drugs Released
9 December 2010
OHE Consulting has released new research on orphan medicinal products (OMPs) in Europe that assesses the effects of the European Union’s 1999 Regulation on Orphan Medicinal…

Access to Orphan Drugs in the EU
21 October 2010
Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE’s Dr…

Biomedical and Health Research Spillovers in the UK
14 October 2010
Research spillovers exist when research by one organisation creates increased output for other organisations that operate in the same or other sector of the economy. Given…

New Antimicrobial Drugs: EU Policy Options
4 October 2010
Antimicrobial resistance to drugs is a growing global public health issue. The EU began a discussion in 2009 about which policies can best encourage the development…